GlassScriptPhysician profile
Amber Rogers
NPI 1114561909
$1,177.59
in general payments reported to CMS, 2019-2025
25 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $420 · 2022: $180 · 2023: $143 · 2024: $201 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $576.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $226.49 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $108.28 | 2021-2023 | Mounjaro |
| Astellas Pharma US INC | $106.01 | 2023-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $91.19 | 2023-2025 | Rexulti |
| Amgen INC. | $64.19 | 2021-2022 | |
| Abbvie INC. | $61.77 | 2021-2023 | |
| Glaxosmithkline, LLC. | $56.43 | 2021-2025 | Shingrix, Bexsero, Arexvy |
| Janssen Pharmaceuticals, INC | $52.77 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.43 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $43.31 | 2021 | |
| Pulmonx Corporation | $43.25 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.57 | 2025 | Caplyta |
| Ultragenyx Pharmaceutical INC. | $30.14 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.62 | 2021-2025 | Xifaxan |
| Dexcom, INC. | $24.42 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $23.50 | 2021 | |
| Pfizer INC. | $18.56 | 2025 | |
| Exact Sciences Corporation | $17.66 | 2024 | Cologuard Collection Kit |
| Organon LLC | $16.15 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.48 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.03 | 2021 | |
| Myriad Genetic Laboratories, INC. | $13.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.64 | 2022 | |
| Biogen, INC. | $12.63 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.